Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries by Abbas Kebriaeezadeh et al.
Kebriaeezadeh et al. DARU Journal of Pharmaceutical Sciences 2013, 21:52
http://www.darujps.com/content/21/1/52RESEARCH ARTICLE Open AccessTrend analysis of the pharmaceutical market in
Iran; 1997–2010; policy implications for
developing countries
Abbas Kebriaeezadeh1,2*, Nasser Nassiri Koopaei1, Akbar Abdollahiasl1*, Shekoufeh Nikfar1 and Nafiseh Mohamadi3Abstract
Background: So far, no detailed study of the Iranian pharmaceutical market has been conducted, and only a few
studies have analyzed medicine consumption and expenditure in Iran. Pharmaceutical market trend analysis
remains one of the most useful instruments to evaluate the pharmaceutical systems efficiency. An increase in
imports of medicines, and a simultaneous decrease in domestic production prompted us to investigate the
pharmaceutical expenditure structure. On the other hand, analyzing statistics provides a suitable method to assess
the outcomes of national pharmaceutical policies and regulations.
Methods: This is a descriptive and cross-sectional study which investigates the Iranian pharmaceutical market over
a 13-year period (1997–2010). This study used the Iranian pharmaceutical statistical datasheet published by the
Iranian Ministry of Health. Systematic searches of the relevant Persian and English research literature were made. In
addition, official government documents were analyzed as sources of both data and detailed statements of policy.
Results: Analysis of the Iranian pharmaceutical market in the 13-year period shows that medicine consumption
sales value growth has been 28.38% annually. Determination of domestic production and import reveals that 9.3%
and 42.3% annual growth, respectively, have been experienced.
Conclusions: The Iranian pharmaceutical market has undergone great growth in comparison with developing
countries and the pharmerging group, and the market is expanding quickly while a major share goes to
biotechnology drugs, which implies the need to commercialization activities in novel fields like pharmaceutical
biotechnology. This market expansion has been in favor of imported medicine in sales terms, caused by the
reinforcement of suspicious policies of policy makers that necessitates fundamental rearrangements.
Keywords: Pharmaceutical market trends, Therapeutic categories, Pharmaceutical biotechnology, CommercializationBackground
Total expenditure on health in Iran is increasing, while the
public sector’s share is decreasing. Private sector expend-
iture as out-of-pocket payment is remarkably high as it ac-
counts for more than 50% of the whole expenditure [1].
The modern Iranian pharmaceutical system commenced
100 years ago with the opening of the first modern-style
pharmacy by German, French, and Austrian pharmacists* Correspondence: kebriaee@tums.ac.ir; abdollahiasl@gmail.com
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distribution, and reproduction in any mediumin Tehran. Pharmacy training was initiated by European in-
structors at Darolfonoon, which was remodeled with the
inauguration of the Tehran Faculty of Pharmacy in 1934
which undertook a very important role in the Iranian
pharmaceutical industry. Established in 1946, Abidi was
the first Iranian pharmaceutical company, followed by
Tolid Darou and Darou Pakhsh in 1958 and 1963, respect-
ively [2]. After the Islamic revolution, two major motions
caused fundamental changes: nationalization of the
pharmaceutical industries, and generic scheme. Govern-
mental industry privatization and transition to the semi-
governmental sector was one of the major actions taken by
the government in the 1988 to 1993 period. This study ex-
amines the present situation of the pharmaceutical systemCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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importing companies, distribution, regulations, human re-
sources in the pharmaceutical system, and market trend
analysis [3].Present situation of the Iranian pharmaceutical industry
Pharmaceutical production consisted mainly of 89 com-
panies in 2010. The market concentration ratio is low. In
2010, the Herfindahl–Hirschman Index (HHI) was 295.11
for the domestic production companies, indicating little
market power. Raw and packaged materials are provided
by the domestic and import suppliers. Regarding sales, ten
top pharmaceutical companies in 2009–2010 are shown in
Table 1. Tamin Pharmaceutical Investment Company (So-
cial Security Organization), Sobhan Pharma Group, and
Shafadarou corporation (Melli Bank Investment Corpor-
ation) are the most important public owners of the
pharmaceutical industry. Based on these structures, phar-
maceutical holdings (Groups) sales are shown in Table 2.
Data reveals an increasing rate of privatization in pharma-
ceutical sector.Import companies
There are 93 private companies engaged in importing
medicine, and 30 designated emergency medicine centers
besides national medicine and medical equipment corpo-
rations. There is Red Crescent (Ministry of Health), Darou
pakhsh trade development (Tamin Investment Corpor-
ation), and KBC (Sobhan Pharmaceutical Group), which
are all public. In 2010, the HHI was 781, which is higher
in comparison with that of the domestic production com-
panies. Ten top importer companies in 2009–2010 are
shown in Table 3.Table 1 Ten top domestic production pharmaceutical
companies in Iran; 2009-2010








4 Farabi 5.3% 23.8%
5 Tehran Chemie 5.2% 29.0%
6 Alborz Darou 3.8% 32.8%
7 Sobhan Darou 3.7% 36.5%
8 Osvah 3.6% 40.1%
9 Dana 2.9% 42.9%
10 Aboureihan 2.8% 45.7%Distribution
There were 35 nationwide drug distribution companies,
among which the first four distribute approximately 70%
of the entire market’s drugs. All major holdings have their
own nationwide drug distribution companies that are
ranked in the top four. HHI was 1387, which was signifi-
cantly higher than that of the domestic production.
Regulations
Passed in 1955, the medicine, drug, food, and drink af-
fairs law act is the cornerstone for the current pharma-
ceutical procedures in Iran. Most of the bylaws and
ordinances are designed and approved in the drug affairs
department [2].
Licensing
Production, importation, and distribution of medicinal
products are performed under strict control by the au-
thorities, and involve registration and licensure by the
food and drug organization (formerly, Undersecretary of
Food and Drug).
Pricing
Medicine price is controlled by the food and drug
organization through pricing commission regulations in
a cost plus basis through comparison with selected com-
panies according to published regulations.
Reimbursement
Medicine cost reimbursement is mainly undertaken by
three major organizations: Social Security Organization
(public), Medical Services Insurance Organization (gov-
ernmental), and Medical Insurance Services Organization
of Armed Forces (governmental), all of which reimburse
the cheapest medicine registered. The emerging supple-
mentary insurance companies are putting constraints on
pharmaceutical expenditure. There is a positive list of
medicines fully covered by the government that contains
specialty drugs.
Human resources
Pharmacists are considered a major source for the
pharmaceutical system. Most of the 13000 pharmacist
society members are involved in pharmacies. About 6%Table 2 Major holdings in domestic pharmaceutical







1 Tamin Investment Corporation 29% 29%
2 Sobhan Pharmaceutical Group 16% 45%
3 Shafadarou Corporation 10% 55%
4 Tehran Chimi Corporation (Private) 10% 65%
Table 3 Ten top importer companies in Iran; 2009-2010




1 Cobel 17.2% 17.2%
2 Akbarieh 12.3% 29.6%
3 Behestan Darou 11.6% 41.2%
4 Shafayab Gostar 8.4% 49.6%
5 Jahan Behbood 5.7% 55.3%
6 Ahran Tejarat 5.0% 60.3%
7 Gostaresh Bazargani Daroupakhsh 4.8% 65.1%
8 Actover 3.4% 68.4%
9 KBC 2.6% 71.0%
10 Kavosh Gostar Darou 2.2% 73.2%
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itself, less than 2% of the trained and scientific workforce
is engaged in research and development.
Active pharmaceutical ingredients
A growing number of companies are engaged in the pro-
duction of Active Pharmaceutical Ingredient (API). Each
holding has its own API-producing branch, and there
are more than 30 companies engaged in production of
APIs. Formal policies of the Ministry of Health actively
promote motions towards independence in the API in-
dustry. Companies active in the field of API production
are mainly possessed by the private sector, contrary to
the finished products and distribution companies [4].
Methods
This is a descriptive and cross-sectional study which in-
vestigates the Iranian pharmaceutical market over a 13-
year period (1997–2010). This study used the Iranian
pharmaceutical statistical datasheet published by the
Iranian Ministry of Health. Drug consumption statistics
are collected by the Food and Drug Organization (FDO)
through the data received from the drug distribution
companies. All distribution companies deliver their data
on drug sales to the pharmacies as a unified format to
the food and drug organization on a monthly basis. That
data, after revision, is published as the Iranian pharma-
ceutical statistical datasheet yearly as sales volume (by
unit) for any medicine delivered, and cost per medicine
unit. Although that data does not represent real drug
consumption and the subsidy paid by the government
and only reveals the sales of drug to the pharmacies, it is
the most unique and convenient method to monitor the
pharmaceutical market. Systematic searches of the rele-
vant Persian and English research literature were made,
using electronic databases in addition to written reports.
Official government documents were also analyzed as
sources of data and detailed statements of policy.Different sources, such as statistics published by the
Iranian Ministry of Health, pharmaceutical production
companies syndicate, and the national medicine assem-
blies were also researched for statistics and data on
medicine consumption in a domestic production and
importation separation basis, production and import-
ation statistics, pharmaceutical expenditure, medicine
consumption per capita, and drug utilization by sales
value in different therapeutic categories.
Results
The trend analysis shows that Iranian pharmaceutical
medicine market has been drastically grown in the recent
decade. In the period, the population of the country has
grown from 61 to 74 million, namely a total and annual
growth of 21.3% and 1.53%, respectively. Total medicine
market sales value reached $2.467 billion in 2010 from
$0.139 billion in 1997, representing a 1669% increase
(Figure 1). The annual growth rate was 28.38%. Domestic
pharmaceutical production sales value reached $1.639 bil-
lion in 2010 in comparison with $0.125 billion in 1997, a
1213% growth. The average annual sales value growth is
9.3%. The correlation coefficient (R2) of 0.9293 shows a
fairly consistent growth, though the 2011 estimate shows a
decrease in market sales value. The imported medicine
market sales value rose to $0.828 billion in 2010 from
$0.015 in 1997, showing a dramatic total growth of 5499%,
and an annual growth of 42.3%. In the period under inves-
tigation, sales value percentile proportion of imports to
total drug consumption has reached 39% from 10.59% in
the base year, showing a huge growth of 28.41%. The aver-
age sales value percentile proportion of imports to total
medicine consumption has been 2.1% (R2: 0.9612)
(Figure 2). The sales value percentile proportion of domes-
tic production to total medicine consumption has reduced
from 89.41% to 61% in 2010, revealing a significant de-
crease of 28%.
Per capita drug consumption sales value
Over the 13-year period, the data indicates that the index
has reached $34.43 from $2.28 in 1997, which shows an
overwhelming growth of 1405%, and an annual average
growth of 10.8% (R2: 0.9235) (Figure 3). These figures show
marked growth in comparison to population growth (20%).
Per capita value of domestic pharmaceutical medicine
consumption
This index has reached $22.86 from $2.05 in 1997, with
a total and an annual growth of 1018% and 10.8%, re-
spectively (R2: 0.9397).
Per capita value of the imported medicine consumption
This index has reached $11.57 from $0.24 in 1997, with
a total growth of 4373% (R2: 0.8907).
Year






























Figure 1 Total, domestic production and imported medicine consumption by value; 1998–2011.
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The index reached an estimated $0.084 in 2011 from
$0.009 in 1997, with a growth rate of 847% (R2: 0.9407)
(Figure 4). The average sales value of domestic and
imported medicines by unit also shows a total growth rate
of 631% (R2: 0.9506) and 1930% (R2: 0.8345), respectively.Y
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Regression line
Figure 2 Sales value percentile proportion of imports and domestic pDrug consumption by therapeutic categorization
(by ATC codes)
As the graph depicts, the market shows a point drop in
the year 2000 that was due to the nationwide currency
exchange rate variation (Figure 5). The data shows that
antiinfectives preparations for systemic use and thenear
004 2006 2008 2010 2012
sumption proportion (value)
 to total consumption proportion (value)
roduction to the total medicine consumption; 1998–2011.
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most shares in the market and have had the steepest
slope among the categories. Alimentary tract and metab-
olism and nervous system products also show high
growth rates. The two recently mentioned categories
contain the most prevalent utilization among all in
terms of volume (data not shown).
Discussion
This study presents the market environment of the
pharmaceutical sector in Iran, and highlights its chal-
lenges and future prospects. In order to study a country’s
medicine market systematically, various indicators can
be applied, e.g. market behavior about specific dosage
forms or quantity or quality trends [3]. Most owners of
the pharmaceutical industry were either dependent on
the former regime or foreigners who left Iran after the
revolution, so young domestic pharmacists began to
manage the pharmaceutical system of the country. Iran-
Iraq War (1980–1988) also prompted the need for strict
monitoring of the market. The revolutionary govern-
ment exerted fundamental changes in the food and drug
organization in order to assess the need for pharmaceu-
ticals in both general society and for the military forces.
With the establishment of the planning office in the food
and drug organization, some experts were ascribed to
closely monitor the needs and prepare the production
and the import scheme. In 1986, the government in of-
fice assumed private ownership and liberalization in the
economic system, which resulted in magnificent growth
in the market. In 1999, the government allowed domes-
tic production companies usage of their free capacity to
cross the borders of planning by the food and drug
organization. In 2001, further liberalization in theY
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Figure 3 Total, domestic production and import value per capita medpharmaceutical system and the lack of subsidized cur-
rency caused an increase in prices. This liberalization in
the pharmaceutical system also augmented imports.
Throughout the period, domestic production constituted
a major share in the market [3]. The major reasons for
the growing demand are as follows [4,5]:
 Iran’s demographic structure and population growth;
 increased insurance coverage of the population;
 increased level of income and gross domestic
product (GDP) per capita;
 incidence of new diseases and epidemiologic
transition, e.g. types of cancer and multiple sclerosis;
 intentionally lowered medicine price; and
 medical sciences advances.
In the period under investigation, accessibility to health
services and insurance coverage has grown remarkably,
possibly as a result of GDP growth. The government has
approached the medicine accessibility positively, and a
number of medicines have been included in the medicine
list. However, insurance coverage has not expanded simul-
taneously and proportionately. Health sector budget share
in the GDP did not develop acceptably, causing a drastic
increase in the public’s out-of-pocket payment. Insurance
coverage expansion was through three major organiza-
tions: the Social Security Organization, Medical Services
Insurance Organization, and Medical Insurance Services
Organization of Armed Forces. The universal insurance
coverage act obliges the population to register for an in-
surance service which contributes to the goal. Iranian
pharmaceutical industries mostly manufacture traditional
medicines, and deficiency in the investments needed for
monoclonal antibodies and other biotechnology-derivedear
004 2006 2008 2010 2012
sumption value
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Average imported medicine unit value
Regression line
Figure 4 Average sales value of the total, domestic production and imported medicines by unit; 1998–2011.
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imported medicine. The Iranian pharmaceutical industry’s
private sector has not yet developed as much as required.
More than 70% of the domestic industries are owned by
the government and its related bodies or the public orga-
nizations. As evidenced by the two existing biotechnology
companies, both of which are privately-owned, privatization
can lead to greater sustainable development in domestic in-
dustries [6,7]. Currently, total pharmaceutical market value
is about $3.2 billion, or as much as $4-4.5 billion according
to some estimates on the real market size [8]. The present
difference between real and estimated value is attributed to
the price suppression policies of the authorities [9]. It
should also be noted that national currency has experi-
enced a drastic devaluation against USD. Iran experiencesYear






























Figure 5 Medicine consumption by value in therapeutic categories; 1an average growth rate of 28.38%, which is significantly
more than developing countries such as China and India
which have around 11 to 15% growth [10,11]. The results
show that the domestic production sales value has grown,
but not in concordance with that of the imported medicine
sales value. The results also imply that the current pharma-
ceutical policies are in favor of imports, as the slope of the
import and domestic production lines illustrate. The rise in
Iranian pharmaceutical expenditure is expected to continue
at a significant, even higher rate than expected from devel-
oping countries, based on factors mentioned above and the
deliberate deficiencies of pharmaceutical policy [12,13].
Medicines are regarded as both public and industry goods.
Iranian patients are entitled to have access to high-quality,
timely, and cost-effective medicine [14,15]. The Iranian88 90
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for years to come. Currently, 20% of Iran’s total health ex-
penditure, on average, goes on medicine (reimbursed by
the insurance organizations, based on their reports to the
supreme insurance council for last year). Antibiotics, anti-
neoplastics and immunomudulating agents (medicines
mostly used for organ transplantation rejection prohib-
ition), antidiabetics, and alimentary tract medications gain
the most value in the market (Figure 5). Regarding sales
volume, analgesics, antibiotics, and second generation anti-
diabetics are the best sellers. Investigating the mostly used
products among the two top categories it is obvious that
pharmaceutical biotechnology derived medicines such as
proteins and monoclonal antibodies take major positions
(results not presented). Considering the items mentioned, it
is concluded that new and high tech medicines are seizing
a large share of the market; which should incite policy
makers to change for the better. If the market continues its
growth, a great financial load will be imposed on the health
system. Iran contains nearly 1% of the world’s population,
but only about 0.3% of the world market, so if the two are
in an agreement, Iran should assume $7-8 billion in 2010,
and $10-12 billion in 2020. Generic medicine use is an im-
portant component of the government’s health plan that
was obligatory through the generic scheme shortly after the
revolution. The policy assisted the country pass the con-
straints of the 1980s, but vitally restricted research and de-
velopment in the domestic industry, while exerting severe
price containment policies [16]. Current issues of interest
for the Iranian pharmaceutical market include a rise in im-
ports and simultaneous fall in domestic production. Low
rates of investment, capital asset substitution, scarce atten-
tion to modern technologies like pharmaceutical biotech-
nology, and a branded medicine market are possible
reasons for this domestic medicine market shrinkage
[17,18]. The investment activity of pharmaceutical compan-
ies is dependant mainly on product demand, profits,
technological developments, and capital availability. It is
vital to notice the steady decrease in investment rate for
capital equipment replacement. This is associated with the
market shift towards imported medicines and the lack of
well-designed, long-term policies to support the domestic
pharmaceutical industry that would potentiate reasonable
conditions to encourage domestic production [19]. Mean-
while vast research projects have been conducted in the
universities and research centers but few of them have been
commercialized into medicines. Performing studies aligned
with the needs of the biopharmaceutical industry could be
seen as a choice. Policy makers and authorities could con-
tribute the national production capabilities by establishing
the basements to commercialize the researches, revising
the policies, forming close relationships and cooperative
committees with the biopharmaceutical industries and ap-
plying evidence based decision making procedures.Conclusions
The absence of significant basic and applied biopharma-
ceutical research that can result in industrial break-
throughs and attain competitive advantage in Iran has
induced a state of regression in the domestic industry
that has accelerated a drain on the capital and energy of
the industry. Such conditions, along with price suppres-
sion, increase imports [20,21]. It is advised that policy
makers take all necessary measures towards establishing
an appropriate pharmaceutical business environment
that favors domestic production, as well as controlling
rising expenditure in the pharmaceutical sector [22]. We
can conclude that the average value of imported medi-
cine per unit is growing, which suggests technological
content is in continuous improvement in comparison
with domestic ones [23-25]. Medicine consumption per
capita shows that this index is high in Iran. Therefore, it
is proposed that conducting applied research projects
ordered by the biopharmaceutical industries along with
preparing the requirements for commercialization of
novel fields like pharmaceutical biotechnology which as-
signs a great share in the national pharmaceutical ex-
penditure be in the top agenda.
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